- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05731206
Hypoallergenicitet hos en hydrolyserad proteinspädbarnsformel (HYPO STORY)
Studie för att bedöma hypoallergenicitet hos en hydrolyserad proteinformel hos barn med bekräftad komjölksallergi
Study to demonstrate hypoallergenicity of a hydrolysed protein infant formula in a population of children with confirmed cow's milk allergy.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The study consists of a double-blind, placebo-controlled food challenge, followed by a single arm open challenge.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Rome, Italien
- Pediatric hospital Bambino Gesù
-
Huvudutredare:
- Alessandro Fiocchi, Prof
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Infants and children aged up to 3 years.
-
Diagnosed with cow's milk allergy (or re-confirmed), within two months prior to the study (challenge day #1), by:
- Physician-supervised double-blind oral food challenge; or
- Physician-supervised open oral food challenge that elicited objective immediate allergic reactions; or
- Report of convincing allergic reaction to cow's milk or a milk-containing food product, in conjunction with presence of milk-specific serum Immunoglobuline E (IgE) level > 0.7 kilounit per liter (U/L) or by skin prick test (wheal size ≥ 3mm).
-
Willing to switch to a different hypoallergenic formula
-
On elimination diet (commercially available, hypoallergenic infant formula ) and free of clinical symptoms, or with controlled stable symptoms, for at least one week preceding the study (challenge day #1).
-
Expected minimal consumption of 144ml of test product/day during the open challenge.
-
Written informed consent provided by parents/guardians, according to local law.
Exclusion Criteria:
- Infants/children who are more suitable to use AAF as first-line formula, including but not limited to those with high risk of anaphylaxis (prior history of anaphylaxis and currently not using eHF) or severe forms of non-IgE-mediated CMA such as eosinophilic oesophagitis, enteropathies, or Food Protein-Induced Enterocolitis Syndrome (FPIES).
- Diagnosis or known allergy to any of the ingredients in the test product.
- Congenital anomalies which will interfere with oral feeding or gastrointestinal tract, other chronic diseases (including but not limited to cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, immunological and endocrine disease), major gastrointestinal disease/abnormalities, or any other medical condition that could interfere with the identification of allergic reactions.
- (Twin / triplet) sibling of an infant/child already participating in the study.
- Investigator's uncertainty about the willingness or ability of the subject and his/her parents to comply with the protocol requirements.
- Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.
- Employees and/or children/family members or relatives of employees of Nutricia Research or the participating study sites.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: hydrolized protein formula
hydrolysed protein formula |
Hydrolyzed protein infant formula |
|
Placebo-jämförare: Control formula
commercially available hypoallergenic infant formula |
commercially available hypoallergenic infant formula |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Hypoallergenicity
Tidsram: 25-35 days
|
The percentage of children tolerating the formula tested by double-blind, placebo-controlled food challenge and a subsequent open challenge. |
25-35 days
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Relevant parameters routinely collected in the clinic
Tidsram: 25-35 days
|
e.g serum IgE results |
25-35 days
|
|
Incidence, seriousness, severity and relatedness of Adverse Events
Tidsram: 25-35 days
|
Safety and tolerance parameters |
25-35 days
|
|
Demographics characteristics
Tidsram: at baseline
|
Demographics characteristics |
at baseline
|
|
Relevant parameters routinely collected in the clinic
Tidsram: 25-35 days
|
e.g. skin prick test results |
25-35 days
|
|
Birth length
Tidsram: at baseline
|
cm |
at baseline
|
|
Birth weight
Tidsram: at baseline
|
g |
at baseline
|
|
anthropometrics
Tidsram: at baseline
|
e.g. weight and lenght |
at baseline
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- SBB22R&40330
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .